Back to search results
NCT02413450

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

Enrolling by Invitation
Not specifiedAges 18–85Observational
Johns Hopkins University
~100 participants
Updated 2026-01-16 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
•Production of cardiomyocytes and engineered tissues from hiPSC-derived cardiomyocytes to be used in mechanistic studies of disease and testing of therapeutic interventions.
Measured over 10 years

Conditions

Inherited Cardiac Arrythmias
Long QT Syndrome (LQTS)
Brugada Syndrome (BrS)
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Early Repolarization Syndrome (ERS)
Arrhythmogenic Cardiomyopathy (AC, ARVD/C)
Hypertrophic Cardiomyopathy (HCM)
Dilated Cardiomyopathy (DCM)
Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
Normal Control Subjects

Explore related trials

Brugada SyndromeCatecholaminergic Polymorphic Ventricular Tachycardia by ECG FindingEARLY REPOLARIZATION ASSOCIATED WITH VENTRICULAR FIBRILLATIONHealthy VolunteersLong QT Syndrome

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Andreas Barth, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All patients and family members 18 years of age or older with inherited cardiac arrhythmias including LQTS, Brugada Syndrome (BrS), cathecholaminergic polymorphic ventricular tachycardia (CPVT) or early repolarization syndrome (ERS) are eligible for enrollment.
All enrolled patients will have undergone clinically indicated genetic testing.

Exclusion

Age \<18 years
\>85 years
pregnant women
life-limiting co-morbidities
immunocompromise

What this trial measures

  • •Production of cardiomyocytes and engineered tissues from hiPSC-derived cardiomyocytes to be used in mechanistic studies of disease and testing of therapeutic interventions.10 years

    Whole Blood drawn on day of informed consent obtained.